Ridinilazole - Summit Therapeutics

Drug Profile

Ridinilazole - Summit Therapeutics

Alternative Names: SMT-19969

Latest Information Update: 27 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Summit plc
  • Developer Summit Therapeutics
  • Class Antibacterials; Benzimidazoles; Pyridines; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Clostridium-difficile-infections

Most Recent Events

  • 27 Mar 2018 Summit Therapeutics plans two phase III trials for Clostridium difficile infections in first quarter of 2019
  • 21 Dec 2017 Ridinilazole licensed to Eurofarma in Latin America
  • 06 Nov 2017 Summit Therapeutics and Wellcome Trust establishes a revenue sharing agreement for commercialisation of ridinilazole for Clostridium difficile infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top